Cargando…

Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States

This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathyanarayanan, Vishwanath, Flowers, Christopher R., Iyer, Swaminathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392782/
https://www.ncbi.nlm.nih.gov/pubmed/32692628
http://dx.doi.org/10.1200/GO.20.00012
_version_ 1783564917160280064
author Sathyanarayanan, Vishwanath
Flowers, Christopher R.
Iyer, Swaminathan P.
author_facet Sathyanarayanan, Vishwanath
Flowers, Christopher R.
Iyer, Swaminathan P.
author_sort Sathyanarayanan, Vishwanath
collection PubMed
description This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval of immunotherapeutic and targeted therapies. These new treatments have had an impact on overall outcomes and have helped determine the design for translational research and future trials. Although most of these novel drugs called “innovators” are initially approved and marketed in the United States, several have also become available in countries such as India. With the expiration of patents, generic versions of innovator drugs have increased and accessibility has improved for patients. The advent of biosimilars is another route for expanding access to biologic compounds. As a result, the development costs for developing these drugs are lower, and consequently, the costs for the patient are often lower. Although the delivery of cancer care is not the same in India as it is in the United States, the introduction of biosimilars and generics has helped bridge the gap. This has made treatment of CLL and lymphoma similar in both countries and has had the same impact on patient outcomes and quality of life. Compulsory licensing for essential medications, as stipulated by the Doha Declaration, and capping of drug prices could improve global access to treatments for CLL and lymphoma.
format Online
Article
Text
id pubmed-7392782
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-73927822020-08-03 Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States Sathyanarayanan, Vishwanath Flowers, Christopher R. Iyer, Swaminathan P. JCO Glob Oncol Original Reports This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval of immunotherapeutic and targeted therapies. These new treatments have had an impact on overall outcomes and have helped determine the design for translational research and future trials. Although most of these novel drugs called “innovators” are initially approved and marketed in the United States, several have also become available in countries such as India. With the expiration of patents, generic versions of innovator drugs have increased and accessibility has improved for patients. The advent of biosimilars is another route for expanding access to biologic compounds. As a result, the development costs for developing these drugs are lower, and consequently, the costs for the patient are often lower. Although the delivery of cancer care is not the same in India as it is in the United States, the introduction of biosimilars and generics has helped bridge the gap. This has made treatment of CLL and lymphoma similar in both countries and has had the same impact on patient outcomes and quality of life. Compulsory licensing for essential medications, as stipulated by the Doha Declaration, and capping of drug prices could improve global access to treatments for CLL and lymphoma. American Society of Clinical Oncology 2020-07-21 /pmc/articles/PMC7392782/ /pubmed/32692628 http://dx.doi.org/10.1200/GO.20.00012 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Reports
Sathyanarayanan, Vishwanath
Flowers, Christopher R.
Iyer, Swaminathan P.
Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
title Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
title_full Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
title_fullStr Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
title_full_unstemmed Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
title_short Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
title_sort comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between india and the united states
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392782/
https://www.ncbi.nlm.nih.gov/pubmed/32692628
http://dx.doi.org/10.1200/GO.20.00012
work_keys_str_mv AT sathyanarayananvishwanath comparisonofaccesstonoveldrugsforlymphomaandchroniclymphocyticleukemiabetweenindiaandtheunitedstates
AT flowerschristopherr comparisonofaccesstonoveldrugsforlymphomaandchroniclymphocyticleukemiabetweenindiaandtheunitedstates
AT iyerswaminathanp comparisonofaccesstonoveldrugsforlymphomaandchroniclymphocyticleukemiabetweenindiaandtheunitedstates